Drugs / ET140203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04502082 | Apr 2021 → Aug 2024 | hepatocellular carcinoma | Eureka Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET140203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04502082 ↗ |
| Action | Deplete | “capable of mediating cell killing by targeting tumor specific intracellular antigens” NCT04502082 ↗ |
| Modality | Cell therapy | “investigate an autologous T-cell therapy for advanced hepatocellular carcinoma (HCC)” NCT04502082 ↗ |